Human STAT1 gain of function with chronic mucocutaneous candidiasis: A comprehensive review for strengthening the connection between bedside observations and laboratory research
Immunological Reviews · 2024-03 · 322 (1) · 81-97
DOI: 10.1111/imr.13300 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunological Reviews, online erschienen am 12.12.2023. Verfasst von Takaki Asano und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Hiroshima University Graduate School of Biomedical and Health Science, Hiroshima, Japan. Hauptthemen laut MEDLINE: Candidiasis, Chronic Mucocutaneous, Aneurysm. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 170 Literaturangaben. Gefördert von: Grants in Aid for Scientific Research from the Japan Society for the Promotion of Science, Practical Research Project for Rare/Intractable Diseases from Japan Agency for Medical Research and Development, AMED.
Abstract (Originalsprache)
Germline human heterozygous STAT1 gain‐of‐function (GOF) variants were first discovered a common cause of chronic mucocutaneous candidiasis (CMC) in 2011. Since then, numerous STAT1 GOF variants have been identified. A variety of clinical phenotypes, including fungal, viral, and bacterial infections, endocrine disorders, autoimmunity, malignancy, and aneurysms, have recently been revealed for STAT1 GOF variants, which has led to the expansion of the clinical spectrum associated with STAT1 GOF. Among this broad range of complications, it has been determined that invasive infections, aneurysms, and malignancies are poor prognostic factors for STAT1 GOF. The effectiveness of JAK inhibitors as a therapeutic option has been established, although further investigation of their long‐term utility and side effects is needed. In contrast to the advancements in treatment options, the precise molecular mechanism underlying STAT1 GOF remains undetermined. Two primary hypotheses for this mechanism involve impaired STAT1 dephosphorylation and increased STAT1 protein levels, both of which are still controversial. A precise understanding of the molecular mechanism is essential for not only advancing diagnostics but also developing therapeutic interventions. Here, we provide a comprehensive review of STAT1 GOF with the aim of establishing a stronger connection between bedside observations and laboratory research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Hiroshima University Graduate School of Biomedical and Health Science, Hiroshima, Japan.
- Department of Genetics and Cell Biology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
ORCID-Profile: Satoshi Okada
Förderung
- Grants in Aid for Scientific Research from the Japan Society for the Promotion of Science
- Practical Research Project for Rare/Intractable Diseases from Japan Agency for Medical Research and Development, AMED
Zitieren
APA
Asano, T., Noma, K., Mizoguchi, Y., Karakawa, S., & Okada, S. (2024). Human STAT1 gain of function with chronic mucocutaneous candidiasis: A comprehensive review for strengthening the connection between bedside observations and laboratory research. Immunological Reviews, 322(1), 81-97. https://doi.org/10.1111/imr.13300
Vancouver
Asano T, Noma K, Mizoguchi Y, Karakawa S, Okada S. Human STAT1 gain of function with chronic mucocutaneous candidiasis: A comprehensive review for strengthening the connection between bedside observations and laboratory research. Immunological Reviews. 2024;322(1):81-97. doi:10.1111/imr.13300
BibTeX
@article{Asano2024,
author = {Asano, Takaki and Noma, Kosuke and Mizoguchi, Yoko and Karakawa, Shuhei and Okada, Satoshi},
title = {Human STAT1 gain of function with chronic mucocutaneous candidiasis: A comprehensive review for strengthening the connection between bedside observations and laboratory research},
journal = {Immunological Reviews},
year = {2024},
volume = {322},
number = {1},
pages = {81--97},
doi = {10.1111/imr.13300}
}
EUVIMED